Evofem Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-550-1900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees30
Next Earnings Date11/6/2019 (Estimated)
OptionableNot Optionable
Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions
What is Evofem Biosciences' stock symbol?
Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."
How were Evofem Biosciences' earnings last quarter?
Evofem Biosciences Inc (NASDAQ:EVFM) announced its quarterly earnings data on Monday, August, 5th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.35). View Evofem Biosciences' Earnings History.
When is Evofem Biosciences' next earnings date?
What price target have analysts set for EVFM?
3 analysts have issued 12-month price targets for Evofem Biosciences' stock. Their forecasts range from $9.00 to $11.00. On average, they anticipate Evofem Biosciences' share price to reach $9.67 in the next twelve months. This suggests a possible upside of 95.3% from the stock's current price. View Analyst Price Targets for Evofem Biosciences.
What is the consensus analysts' recommendation for Evofem Biosciences?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evofem Biosciences.
Has Evofem Biosciences been receiving favorable news coverage?
Media headlines about EVFM stock have trended negative recently, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Evofem Biosciences earned a news sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Evofem Biosciences.
Are investors shorting Evofem Biosciences?
Evofem Biosciences saw a decrease in short interest in September. As of September 30th, there was short interest totalling 783,300 shares, a decrease of 6.1% from the August 30th total of 833,800 shares. Based on an average daily trading volume, of 30,000 shares, the short-interest ratio is presently 26.1 days. Approximately 4.1% of the shares of the stock are short sold. View Evofem Biosciences' Current Options Chain.
Who are some of Evofem Biosciences' key competitors?
Some companies that are related to Evofem Biosciences include Spectrum Pharmaceuticals (SPPI), Odonate Therapeutics (ODT), TherapeuticsMD (TXMD), Phibro Animal Health (PAHC), ANI Pharmaceuticals (ANIP), Amneal Pharmaceuticals (AMRX), Y-mAbs Therapeutics (YMAB), ZEALAND PHARMA/S (ZEAL), Athenex (ATNX), Eagle Pharmaceuticals (EGRX), Dova Pharmaceuticals (DOVA), G1 Therapeutics (GTHX), CannTrust (CNTTF), Cara Therapeutics (CARA) and Principia Biopharma (PRNB).
What other stocks do shareholders of Evofem Biosciences own?
Who are Evofem Biosciences' key executives?
Evofem Biosciences' management team includes the folowing people:
- Ms. Saundra Pelletier, CEO & Director
- Mr. Justin J. File, Chief Financial Officer (Age 49)
- Dr. Kelly Culwell, Chief Medical Officer
- Mr. Jason Abrams, Accounting Mang.
- Mr. Alexander A. Fitzpatrick, Exec. VP, Gen. Counsel & Sec. (Age 52)
How do I buy shares of Evofem Biosciences?
Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Evofem Biosciences' stock price today?
One share of EVFM stock can currently be purchased for approximately $4.95.
How big of a company is Evofem Biosciences?
Evofem Biosciences has a market capitalization of $230.67 million. The biotechnology company earns $-125,710,000.00 in net income (profit) each year or ($5.74) on an earnings per share basis. Evofem Biosciences employs 30 workers across the globe.View Additional Information About Evofem Biosciences.
What is Evofem Biosciences' official website?
How can I contact Evofem Biosciences?
Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]
MarketBeat Community Rating for Evofem Biosciences (NASDAQ EVFM)
MarketBeat's community ratings are surveys of what our community members think about Evofem Biosciences and other stocks. Vote "Outperform" if you believe EVFM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVFM will underperform the S&P 500 over the long term. You may vote once every thirty days.
